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Neoplastic tissues are composed not only by tumor cells but also by several
non-transformed stromal cells, such as cancer-associated fibroblasts, endothelial and
immune cells, that actively participate to tumor progression. Starting from the very
beginning of carcinogenesis, tumor cells, through the release of paracrine soluble factors
and vesicles, i.e., exosomes, modify the behavior of the neighboring cells, so that they
can give efficient support for cancer cell proliferation and spreading. A mandatory role in
tumor progression has been recently acknowledged to metabolic deregulation. Beside
undergoing a metabolic reprogramming coherent to their high proliferation rate, tumor
cells also rewire the metabolic assets of their stromal cells, educating them to serve
as nutrient donors. Hence, an alteration in the composition and in the flow rate of
many nutrients within tumor microenvironment has been associated with malignancy
progression. This review is focused on metabolic remodeling of the different cell
populations within tumor microenvironment, dealing with reciprocal re-education through
the symbiotic sharing of metabolites, behaving both as nutrients and as transcriptional
regulators, describing their impact on tumor growth and metastasis.
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INTRODUCTION
Tumor Microenvironment
A solid tumor is a dysfunctional neoplastic tissue characterized by uncontrolled growth and chaotic
histological organization and it is composed, in addition to cancer cells, by heterogeneous subsets
of non-transformed cells, such as mesenchymal stem cells, fibroblasts, endothelial cells, adipocytes
and immune cells, establishing a complex tumor microenvironment (TME) with peculiar
structural and biophysical characteristics [i.e., altered extracellular matrix (ECM) composition,
acidity and hypoxia]. The features of the neoplastic parenchyma are well instructed through a
complex interplay between cancer and stromal cells, orchestrated by soluble factors, metabolites,
extracellular vesicles (EVs), as well as cell-to-cell interaction.
In physiologic conditions fibroblasts are the main cellular component of connective tissue and
they are involved in providing structural scaffolding and trophic ancillary function for the epithelial
cells of the tissues (1). In tumors, cytokines released by cancer cells convert fibroblasts into a
permanently activated, myofibroblast-like, form called cancer associated fibroblasts (CAFs) (2).
This chronic activation of fibroblasts within TME is crucial for cancer progression. Indeed, CAFs
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are responsible for an abnormal ECM deposition and
remodeling, for a persistent inflammation mediated by soluble
factors (i.e., cytokines) (SDF-1, CXCL14, etc.) leading to new
vessels formation and recruitment of immune cells within the
TME, events particularly important for the nutrients supply
and metastatic dissemination, respectively (3). CAFs also
exert an immunomodulating role, mainly by enhancing the
M2/M1 macrophage and the Th2/Th1 ratio (4, 5). Besides
their immunomodulating and pro-angiogenic activity, CAFs
are able to promote epithelial–mesenchymal transition (EMT)
in cancer cells, conferring them proinvasive and stem-like
features (6). Finally, CAFs play a mandatory role in cancer cells
dissemination, since they can escort metastatic cancer cells in the
bloodstream, favoring their implantation at distal sites (7).
Mesenchymal stem cells (MSCs) are multipotent stromal
cells recruited into TME mainly from adipose tissue and bone
marrow in response to several growth factors, i.e., platelet
derived growth factor (PDGF), vascular endothelial growth
factor (VEGF), transforming growth factor-β (TGF-β) as well
as EVs released by cancer cells (8). MSCs possess self-renewal
ability and are able to differentiate into several cell types within
TME, such as CAFs. For example, in neuroblastoma tumor
CAFs share phenotypic and functional characteristics with bone
marrow-derived MSCs (9), while in vitro conditioning of bone
marrow-derived MSCs cells with tumor-derived medium lead
to the acquiring of a CAF-like phenotype sustaining tumor
growth both in vitro and in vivo (10). In addition to the pro-
tumorigenic functions, broadly shared with CAFs, MSCs show an
immunosuppressive role in both prostate and melanoma cancer
models (11, 12).
Neo-angiogenesis, the growth of new blood vessels from the
existing vasculature, is a key step in tumor progression. Under
the stimulation of pro-angiogenetic cytokines, endothelial cells
within TME provokes a wide but disorganized rearrangement of
vessel architecture characterized by altered permeability which is
crucial for tumor cells metastatic spreading. In addition, tumor
endothelial cells can secrete angiocrine factors, such as CSF-1 or
interleukin (IL)-8 (13) promoting cancer cells migration along
with neutrophils infiltration, hence widening their functions in
tumor progression (14).
Tumor- or CAF-derived cytokines also are able to induce
monocytes recruitment within the tumor mass where they were
activated to M1-like macrophages by CSF-1 and IFN-γ (15).
Conversely, macrophages stimulation with type 2 T helper cell
cytokines, such as IL-4 and IL-10, leads to phenotype called
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stimulating factor; CXCL, chemokine (C-X-C motif) ligand; EMT, epithelial-to-
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M2-like endowed with pro-tumor characteristics, likely taking
part in all steps of the metastatic route (16).
Tumor-associated neutrophils (TANs) are divided into
two sub-populations, showing antitumoral activity (N1-like
phenotype) or protumoral activity (N2 phenotype). Neutrophils,
recruited in TME by CXCL2 and CXCL5 cytokines, actively
participate in the metastatic process by enhancing tumor cell
expression of pro-metastatic genes (15), as well as associating
with circulating breast tumor cells, helping them to proliferate
once they reach the secondary site (11).
Many lymphocytes subtypes are present in TME as CD4+
helper cells, immunosuppressive regulatory T-cells (Tregs)
and CD8+ cytotoxic T-cells, recruited by several chemokines
produced by cancer and stromal cells. The histological origin,
the composition and the density of the cells that constitute
tumor-infiltrating lymphocytes, together with hormonal context
within TME can determine tumor progression and clinical
outcome. For example, a lot of evidence have addressed the
role of cytotoxic CD8+ T cells, whose presence and activity is
associated with a good prognosis, while the infiltration of Tregs,
an immunosuppressive T cell subpopulation, has been shown to
be associated with poor prognosis in several tumors (17).
Adipocytes are recently emerging as important contributors to
cancer progression. Cancer cells through chemokines secretion
can convert adipocytes into their activated form Cancer-
Associated Adipocytes (CAAs), that has been reported to
promote IL-6-mediated EMT in cancer cells (18). CAAs-secreted
leptin has a proliferative effect on cancer cells (19) as well as a
pro-angiogenic role (20). On the contrary, adiponectin secretion
decreases in CAA with respect to normal adipocytes, suggesting
an anti-proliferative effect of this adipokine on cancer cells (19).
Recent advances in tumor biology showed the importance of
a highly tuned exchange of nutrients within TME, impacting
on tumor progression (21). A consequence of the cytokines-
mediated cross-talk between cancer and stromal cells is the
metabolic reprogramming of all cellular components of the
tumor, aimed at maximizing the proliferative capacity of tumor
cells. In this view CAFs, which are themajor component of tumor
stroma, together with adipocytes, give a feed support to tumor
cells, increasing their growth rate. In addition, some nutrients
exchanged in the TME, also play an essential signaling function
acting as epigenetic switches, leading to activation of EMT and
inhibition of immune cell response. Themultifaceted significance
of nutrients exchange is discussed in the chapters below.
Metabolic Deregulation in Cancer
A tumor, consisting of a heterogeneous and complex network
of cancer and stromal cell populations, needs to adapt
all the metabolic functions to support the demands of
uncontrolled growth and to support disease progression.
The metabolic alterations of a tumor come from both the
oncogenic signaling that orchestrate distinct metabolic pathways
and the environmental context that promotes nutrient-based
intercellular cross-talk and/or competition.
Actually, it is widely recognized that cancer cells need to
meet their bioenergetic and biosynthetic demands to maintain
a high tumor cell growth rate. Tumor cells require a high rate
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of biosynthesis of macromolecules (lipids, amino acids, nucleic
acids) in order to maintain the cellular redox balance and, at
the same time, to compensate their energy-consuming processes,
ultimately culminating in fueling tumor growth and progression.
However, the metabolic reprogramming of cancer cells is crucial
also for the signaling role exerted by the metabolites.
Intriguingly, the metabolic flux is mainly derived from the
glucose in cancer cells, known as the Warburg effect, that is
the ability of cancer cell to massively upload glucose, thanks to
the upregulation of glucose transporters GLUT1-3, in order to
(i) provide precursors and intermediary metabolites, useful for
the tumor-associated biosynthetic machinery, and to (ii) produce
high amounts of lactate, even in the presence of oxygen.Warburg
metabolism is one of the most commonly observed examples
of metabolic reprogramming in highly proliferating cells, such
as cancer cells and non-transformed cells (i.e., T lymphocytes),
taking advantage from the rapid production of ATP and the
synthesis of glucose-derived macromolecules (22).
The collateral metabolic fluxes arising from aerobic glycolysis
lead to the activation of specific pathways such as the pentose-
phosphate-pathway (PPP) and the one-carbon metabolism. PPP
is important for tumor cells as it generates pentoses useful
for DNA/RNA synthesis and feeds the nicotinamide-adenine
dinucleotide phosphate (NADPH) pool, which is needed for
fatty acid synthesis and cell survival under oxidative stress
conditions. The harsh TME, as well the oncogenic background,
are responsible of the increase of reactive oxygen species
(ROS) in tumor cells. These highly reactive molecules can
detrimentally modify the intracellular environment as well as
activate certain pro-tumoral signaling pathways, under certain
sub-toxic levels. Accordingly, to challenge the toxic levels of
ROS, tumor cells increase their antioxidant capacity to allow
cancer progression and PPP activation is oriented in such
way. Oxidative stress can be counteracted by the production
of NADPH by the oxidative branch of the pentose phosphate
pathway, as it is used by the glutathione reductase enzyme in
the reduction reaction of oxidized glutathione (GSSG). To note,
glutathione (GSH) is the one of most important antioxidant
molecule within the cell, it is synthesized from glutamine carbons
and conditions of oxidative stress increase the conversion of
GSH (reduced, physiological form) to GSSG (oxidized), which
is potentially toxic for the cell, as it acts as a pro-oxidant
(23). The deregulation of glutathione metabolism is broadly
identifiable in the majority of cancers as the genes involved
in GSH turnover or utilization are under the transcriptional
control of classical tumorigenic pathways, primarily the nuclear
factor erythroid 2-related factor 2 (NRF2) signaling which
drives the antioxidant response and control the transcription of
glutamate-cysteine ligase, the first enzyme of the cellular GSH
biosynthetic pathway. In addition, the hypoxic signaling is a
driving force for the activation of GSH production and it has
been associated with the enrichment of breast cancer stem cell
niche following chemotherapy treatments (24). GSH alterations
have been identified in metabolically deregulated tumors, such
as tumors deficient for fumarate hydratase enzyme. Strikingly,
the accumulation of fumarate in FH-deficient cancer cell lines
leads to the formation of a peculiar molecule between fumarate
and glutathione (GSH), which depletes intracellular NADPH
and enhances oxidative stress (25). Also, in MYC-driven liver
tumors, particular for a decreased incorporation of glutamine,
the attenuation of expression of glutamate-cysteine ligase
contributes to GSH depletion (26). A key role of glutathione
is also emerging in the context of tumor microenvironment.
In particular, CAFs were shown to diminish the accumulation
of genotoxic agents in cancer cells in a glutathione-dependent
manner. In fact, CAFs release high levels of thiols, including
glutathione and cysteine, which increase intracellular GSH levels
in tumors counteracting drug-dependent oxidative stress and
apoptotic response (27, 28). Furthermore, glycolysis can divert
glucose-derived intermediates to one-carbon pathway that is
important for serine synthesis (29). It supplies methyl groups
to the one-carbon and folate pools, contributing to amino acid
and nucleotides synthesis, methylation reactions, and NADPH
production. Finally, the Warburg-associated fermentation of
pyruvate into lactate, catalyzed by lactate dehydrogenase A
enzyme, culminates in its extrusion in the extracellular milieu
via the monocarboxylic acids transporter MCT4. Lactate release,
coupled with H+, increases external acidity and deliver to TME
a peculiar molecule losing its classification as waste product, as it
plays both a signaling and a metabolic role, thereby altering the
immune cell landscape, increasing tumor invasive capacity and
supplying an appealing carbon source for other cell populations
(30) (see below).
Warburg metabolism is an aspect of a highly multilayered
cancer metabolism, as cancer cells have adapted multiple
mechanisms to exploit metabolic substrates through
mitochondria. To note, many reactions of the tricarboxylic
acid (TCA) cycle are reversible and multiple mitochondria-
associated anaplerotic circuitries ensure such a metabolic
adaptation of cancer cells.
In addition to glucose-derived pyruvate, fatty acids (FAs) and
amino acids can feed the TCA cycle to sustain mitochondrial
activity in malignant cells and produce ATP via oxidative
phosphorylation. A key role of the TCA cycle in proliferating
cells is to act as a biosynthesis hub and this function differs
from that occurring in non-proliferating cells, where TCA cycle
serves to provide the maximal ATP production. During tumor
cell proliferation, however, much of the carbon that enters the
TCA cycle is used in biosynthetic pathways. In this scenario,
tumormitochondrial metabolism represents a cataplerotic center
by providing building blocks for anabolic processes. Synthesis
of lipids (fatty acids, cholesterol, and isoprenoids) is a crucial
example of cataplerosis in tumor cells and the activation of
lipid biogenesis could play an active role in cell transformation
and cancer development, as lipids have important roles in
membrane structure, cellular signaling and protein regulation,
beyond energetics. Glucose is a major lipogenic substrate as it can
be oxidized and mediates the transfer of mitochondrial citrate
out to the cytosol to be converted to oxaloacetate (OAA) and
the lipogenic precursor acetyl-CoA, which can either be used for
fatty acid and cholesterol synthesis or for epigenetic purposes
(i.e., acetylation reactions), by providing a pool for chromatin-
modifying enzymes such as the acetyltransferases (31). However,
the biosynthesis of fatty acid chains, upon conversion of citrate
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to acetyl-CoA via ATP-citrate lyase (ACLY), is sustained by the
carboxylation of cytosolic acetyl-CoA by acetyl-CoA carboxylase
(ACC) to produce malonyl-CoA, which is further assembled into
long fatty acid chains by fatty acid synthase (FASN). As ACLY,
ACC, and FASN are frequently upregulated in tumor cells and
their inhibition reduces tumor growth, it is widely recognized
that the increased capacity for producing lipids de novo is a
crucial determinant for the tumor progression. In addition,
cholesterol synthesis plays a role in the tumor malignancy, as
the interference with such pathway through statins treatment
provokes a detrimental effect on tumor growth in vitro and in
vivo (32).
The major anaplerotic substrate in growing cells is glutamine,
the most rapidly consumed nutrient by many human cancer
cells. Indeed, most of them display addiction to glutamine,
thereby boosting its uptake mainly through SLC1A5/ASCT2
transporter, and its catabolism (glutaminolysis) via the activity
of mitochondrial glutaminolytic enzymes, glutaminase and
glutamate dehydrogenase. Glutamine entry and metabolism is
mainly supported by c-Myc, a transcription factor upregulated in
several cancer cells. To this end, c-Myc induces the transcription
of glutamine transporters, and of glutamine-utilizing enzymes,
such as glutaminase, phosphoribosyl pyrophosphate synthetase
and carbamoyl-phosphate synthetase 2.
Glutamine is important for energetic demands of cancer cells
as it provides carbons to replenish the TCA cycle. However, it
also provides nitrogen for biosynthesis of purine and pyrimidine
nucleotides, as well as of nonessential amino acids. Glutamine
metabolism also contributes to the production of glutathione,
thus playing a role in the cellular anti-oxidant defense, and serves
as a precursor to lipid synthesis via α-ketoglutarate (KG)-to-
citrate conversion namely reductive carboxylation (33, 34). In
addition, many epigenetic modifications and cellular processes
are regulated by glutamine-derived α-KG, which is a cofactor
of dioxygenase enzymes, including the ten eleven translocases
(TET) family and the Jumonji (JMJ) family, thereby affecting,
respectively, DNA and histone demethylation (35).
In keeping, in addition to catabolic, energetic and anabolic
requirements for cancer growth by exploiting TCA cycle, an
intracellular signal transduction cascade is mediated by other
TCA cycle metabolites (36, 37). In tumors harboring the loss of
the mitochondrial enzymes succinate dehydrogenase or fumarate
hydratase, the respective accumulation of succinate or fumarate
has been shown to inhibit the enzymatic activity of α-KG-
dependent dioxygenases. Hence, these enzymes are important
for different purposes such as hypoxia inducible factor (HIF)-1
stability, as well as epigenome rewiring. In keeping, in tumors
that have lost succinate dehydrogenase or fumarate hydratase,
HIF-1 is activated under normoxic conditions, resulting in the
activation of pseudohypoxic pathways and in the enhancement
of tumor malignancy (38).
Thus, beyond the genetic alterations, the ability of tumor
cells to engage different metabolic behaviors according to the
metabolic scenario provided by the microenvironment (oxygen
levels, austere availability of nutrients, stromal cues) greatly
contributes to a high metabolic plasticity which consequently
increases tumor heterogeneity. Indeed, a tumor cell needs to face
the environmental scenario, by displaying a metabolic plasticity
useful to orchestrate the selection, the upload and the consequent
exploitation of the available nutrients in the TME. Thus, the
metabolic reprogramming occurring in a cancer cell encompasses
multiple strategies, among which is a non-cell autonomous one,
mainly involving the tumor-associated stromal components that
supply nutrients and establish metabolic networks with tumor
cell compartment, thereby shaping their malignant phenotype.
Nutrients Exchanged in TME
Besides the metabolic reprogramming of a tumor cell harboring
high mutational landscape, recent discoveries have highlighted
nutrients available in the TME as crucial molecules acting on the
acquisition of a peculiar metabolic and phenotypic plasticity in
tumor cells allowing them to adapt to the peculiar features of
the TME they face with (e.g., cytokine delivery, oxidative, acidic,
and nutritional stress). Tumor-associated stromal and tumor
populations dynamically communicate each other through
metabolic connections, causing a reciprocal tumor-stroma
metabolic interplay. Such metabolic symbiosis reasonably have
the advantage to supply each other different metabolites
able to reprogram anabolic and catabolic processes in the
recipient subpopulations (Figure 1). Of note, nutrients arisen by
stromal populations can overcome metabolic constrains within
the tumor, circumventing oncogenes or tumor suppressors
regulation of several metabolic enzymes, thus rewriting cancer
mass evolution.
Several nutrients will be exchanged within TME, as
explained below.
Lactate
Mitochondrial exploitation of lactate over glucose has been
reported in human lung tumors, highlighting the contribution
of stroma for anabolic purposes and TCA replenishment
driven by such metabolite (39). A clear lactate-based tumor-
stroma cross-talk has been reported in several tumor models,
including the prostate carcinoma. CAFs predominantly exhibit
aerobic glycolysis and secrete lactate through monocarboxylate
transporter (MCT)-4, whose expression is under the redox or
succinate-dependent HIF-1 control (40, 41). Cancer cells educate
CAFs to secrete lactate, exploiting directly the environmental
lactate, uploaded through MCT-1. Once imported, lactate is able
to rewire cancer cell metabolism, causing a shift from glycolysis
to oxidative phosphorylation (OXPHOS) (42). The inward
of stromal lactate provokes the unbalance of NAD+/NADH
ratio (see the lactate-to-pyruvate conversion and its oxidation),
causing ad hoc adaptive changes in cancer cells, such as
sirtuin1-mediated de-acetylation/activation of the transcriptional
co-activator peroxisome proliferator-activated receptor-gamma
coactivator-1 (PGC-1α). Thismolecular signature has been found
as crucial for the enhancement of the tumor mitochondrial
mass and function of stroma-reprogrammed prostate cancer
cells, as reported in other models of tumor progression (43,
44). Moreover, the simultaneous increase of the GLUT-1 carrier
in CAFs, as well as activation of the mitochondrial pyruvate
dehydrogenase complex, concur to significantly reprogram
the metabolism of both tumor and stromal compartments
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FIGURE 1 | Nutrients-based cross-talks between stromal and cancer cells in TME. Resident and recruited stromal cells (CAFs, endothelial, adipocytes, T cells and
macrophages) often are phenotypically conditioned by nutrients released by cancer cells, thereby provoking a both reactive and immunosuppressive environment.
Cancer cells are educated by stromal nutrients to undergo a metabolic and phenotypic reprogramming, both crucial for the cancer metastasis and progression. The
main exchanged nutrients (in bold) promote reciprocal phenotypic effects (in red) in stromal and tumor compartments.
establishing ametabolic symbiosis (45, 46). The in vitro definition
of such metabolic symbiosis has been confirmed in vivo by
recent isotope tracer measurements, showing a rapid exchange
of lactate between the tumor and circulation in several cancer
models (39, 47). Interestingly, the MCT-mediating lactate influx
and efflux activity involves protons (H+), thereby leading to
an apparent paradox. As several accessory cells in TME concur
to decrease extracellular pH [due to the overexpression of
carbonic anhydrases or proton pumps, commonly occurring
in both cancer cells and CAFs (48, 49)], lactate/H+-coupled
transport by MCTs tends to drive lactate from the interstitium
into tumor cells (50), allowing them to anabolize this nutrient
(51). Furthermore, the physical association between carbonic
anhydrases (CA) and lactate transporters MCT-1/4 plays a key
role in the regulation of the directional flux of lactate, as
well as in the protonation/deprotonation of proteins, thereby
affecting their functions. CAII is associated to the cytosolic
part of the MCT transporters, while CAIX is associated to
the extracellular face and MCT-assembled CD147 chaperone.
MCT-associated CAs non-enzymatically cooperate to drive the
lactate/H+ symport/export in/by cancer cells. Indeed, protons
diffuse very slowly within the cell (52); for this reason, in
order to allow a more efficient extrusion of H+ and lactate
from the cell, the MCT does not extract protons directly from
cytosol, but rather from protonated residues located in a peculiar
antenna of CAII. Similarly to the cytoplasm, the diffusion of
H+ in the extracellular space is restricted and protons have
to be removed from the extracellular side by CAIX, shuttled
to protonated residues and then released to the extracellular
space. Hence, lactate bi-directional flux is strictly linked to
acidity, both intracellular and extracellular, and mostly to CAs
activity. Fascinatingly, as these enzymes links acidity to 1-C
metabolism, catalyzing the formation of both H+ and HCO−3 ,
it is conceivable that lactate flux leads to regulation of one
carbon metabolism as well. Importantly, besides its role in the
modulation of MCT-mediated lactate transport into cancer cells,
the high amount of H+ within the TME can modify other
aspects of tumor metabolism, as it promotes a preferential
exploitation of glutamine and lipids—as sources of energy
and biosynthesis—in cancer cells, over the canonical glycolytic
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metabolism. Indeed, a decrease in HIF1α activation (resulting
from direct acetylation) concomitantly with a reduction in the
expression of glycolytic enzymes as well as the glucose transporter
GLUT1 and the lactate transporter MCT4 has been reported
(53, 54). Also, acidosis drives the reprogramming of lipid
metabolism by triggering an increase in HIF2α activity which
stimulates the reductive and oxidative glutamine metabolism,
ultimately sustaining the co-existence of synthesis and oxidation
of Fas (55). Notably, the newly synthetized lipids, stored in lipid
droplets, represent a readily available energy to support anoikis
resistance and invasiveness in cancer cells adapted to the acidic
conditions (56).
Finally, immune cells may be forced to experience
environmental lactate with beneficial or detrimental
consequences on their differentiation. Indeed, in a prostate
cancer model, lactate released by glycolytic CAFs causes a
clear shaping of T-cell polarization, by reducing the percentage
of the anti-tumoral Th1 subset cells and increasing pro-
tumorigenic Treg cells subpopulation. Both Th1 and Treg
cells are reprogrammed by an activation of a lactate-driven
epigenetic pathway, causing activation of T-bet or NF-kB/FoxP3
transcription factors. This lactate-based reprogramming of
T-cell response leads to enhance malignancy of prostate tumors,
thereby confirming the immunomodulatory role of lactate
(51). Furthermore, cancer cell-derived lactate is able to polarize
M1 macrophages into M2 ones, activating different signaling
cascades (i.e., VEGF, arginase-1) in macrophages undergoing
pro-tumor differentiation (57). Notably, another signaling
role of the environmental lactate has been investigated in
endothelium as lactate could be up-taken by endothelial cells
through the MCT-1, thus stimulating the autocrine NF-κB/IL-8
(CXCL8) pathway which affects tumor angiogenesis in terms of
endothelial migration, vessels permeability andmorphology (58).
Importantly, besides the canonical role as nutrient, lactate has
been shown to act as a hormone, as it is able to activate signaling
pathways downstream the hydroxycarboxylic acid receptor 1,
formerly known as G protein-coupled receptor 81 (GPR81). This
receptor, sensitive to low concentrations of lactate (1–5mM),
is coupled to Gi/q, and activation of the receptor results in
decreased cellular levels of cAMP and increased cellular levels
of Ca2+, leading a fascinating hypothesis of an autocrine and
paracrine role of lactate in cancerous and stromal cell types via
surface receptor (59, 60). Very recently, another non-nutritional
role of lactate has been reported by Zhang et al. (61). These
authors reported that lactate produced in hypoxic environment
is involved in a peculiar post-transcriptional modification of
histones (i.e., lactylation), a process occurring with different
temporal dynamics from acetylation and, so far, involved in
wound healing and pro-inflammatory signals (61). Although
the role of lactylation in TME deserves future considerations,
it is likely that this hypothesis deserves consideration in
future studies. However, the lack of definitive information
regarding the microenvironmental fluxes of lactate in the
different cellular compartments highlights the general need
for enlarging and setting new tracing studies in the tumor
extracellular milieu.
TCA Intermediates
Oncometabolites are a group of metabolites, including succinate,
fumarate, and 2-hydroxyglutarate, accumulated in cancer cells
generally as a consequence of mutations in genes coding for
the related metabolic enzymes, that are succinate dehydrogenase
(SDH), fumarate hydratase, or isocitrate dehydrogenase, or of
alterations in their enzymatic activity (62). These metabolites
are involved in the dysregulation of several cellular processes,
mainly through the competitive inhibition of α-KG-dependent
dioxygenases, causing pseudohypoxia via HIF-1 stabilization,
protein post-transcriptional modifications, as well as epigenetic
alterations in cancer cells. Mutations of SDH subunit genes
are recurrent in some cancer types including hereditary
pheochromocytoma syndrome and paraganglioma. In any case,
there is a loss of function of the SDH enzyme, causing
succinate accumulation (63, 64). Germline mutations in the
SDH subunits have also been shown to cause gastrointestinal
renal, pancreatic neuroendocrine, thyroid, and neuroblastoma
tumors (65), although SDH activity can also be epigenetically
inhibited via the binding of the chaperone tumor necrosis factor
receptor-associated protein 1 (49), or through the competitive
inhibition of the metabolite itaconate highly enriched in reactive
macrophages (66). Increased concentrations of succinate may
induce metabolic reprogramming within TME and concur
to promote cancer progression. Accumulation of succinate is
correlated with a state of pseudohypoxia, due to its ability to
inhibit prolyl hydroxylation of HIF-1α, leading to stabilization
of the transcription factor and activation of HIF-controlled
genes involved in glycolysis, angiogenesis, and EMT (67).
Moreover, accumulation of fumarate can reduce the expression
of the anti-metastaticmiRNA clustermir-200ba429, by inhibiting
demethylation of the CpG islands in the regulatory region via
regulation of DNA demethylases TETs. This epigenetic rewiring
promotes activation of EMT programme and the increase of
metastatic potential in a model of renal cancer (38).
Moreover, succinate post-translationally modifies lysine
residues of proteins through succinylation, including L-lactate
dehydrogenase A, glyceraldehyde 3-phosphate dehydrogenase,
glutamate carrier-1, uncoupling protein-1 and malate
dehydrogenase, all enzymes involved in the reprogramming of
cancer cell metabolism (68, 69).
Beside the direct role of oncometabolites in those cancer
cells undergoing their accumulation, a new original view also
supports the oncometabolites as signaling molecules, secreted
by dying cells or by neighboring stromal populations. In this
line, we have recently reported that exposure of prostate cancer
cells to CAFs, while undergoing mitochondrial deregulation and
OXPHOS addiction, leads to the accumulation of TCA cycle
intermediates, consistently with lactate oxidative exploitation
(51). Cancer cells, uploading lactate secreted by CAFs, fuel TCA
cycle and accumulate succinate and fumarate, likely linked to
their ability to drive a pseudohypoxic HIF-1-mediated EMT
motility (51). Upon deregulation of TCA, succinate and fumarate
are also secreted in TME, although indications on their specific
destiny are lacking. In keeping with a role as extracellular signal,
succinate can bind to its cognate receptor namely SUCNR1 (68).
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SUCNR1, belonging to the family of G protein-coupled receptors,
is expressed in kidney, liver, brain, bone marrow, as well as in
several cancers (70), and is reported to control cell proliferation,
migration, capillary formation and development of new vessels
formation, VEGF secretion, as well as stem cell functions (71, 72).
Cancer cells can either accumulate succinate, or eventually
upload it from the TME. Indeed, a plasma membrane Na(+)-
dependent dicarboxylic acid transporter NaDC3 (also called
SLC13A3), able to specifically upload succinate, has been
reported in prostate cancer cells. The real contribution of
extracellular succinate is not clear, as the block of the
succinate plasma membrane carrier is not sufficient to inhibit
cancer growth in a PTEN-loss model of prostate cancer,
while succinate-supported respiration is mandatory for prostate
cancer malignancy (73). During inflammation, succinate may
be secreted by inflammatory macrophages and accumulate
into TME (74), as reported in murine ischemic tissues (75),
central nervous system inflammation and in rheumatoid arthritis
inflammation. Interestingly, macrophages express GPR91 and, in
response to inflammatory signals like lipopolysaccaride, activate
a GPR91-mediated signal transduction that sustains the pro-
inflammatory phenotype and leads to IL-1β production (76).
This represents a novel mechanism by which succinate fuels
inflammation in an autocrine manner to sustain and amplify the
inflammatory response (77).
However, fascinating evidence report that cancer cell-secreted
succinate elicits M2 macrophage polarization and positively
regulates cancer metastasis via SUCNR1 (78), thus enlarging
the class of tumor metabolic factors affecting TME and tumor
phenotypic rearrangement.
Citrate
Citrate is the primary substrate for fatty acid synthesis and
is metabolized in the cytoplasm by ATP-citrate lyase to serve
acetyl-CoA moieties for lipid synthesis. Citrate-derived acetyl-
CoA also contributes to amino acid synthesis, as well as to protein
acetylation (79, 80), both processes critical for proliferating cells.
Sources of citrate for cancer cells are their own Krebs cycle,
reductive carboxylation of α-KG originating from glutaminolysis
(81), as well as the direct importation from TME through a
plasma membrane-specific variant of the mitochondrial citrate
transporter (82). Consistent with the hypothesis of extracellular
citrate as a key nutrient able to affect cancer aggressiveness the
blocking of the plasma membrane citrate carrier (variant of the
SLC25A1), expressed in several malignant cancers, results in
decreased tumor growth in immunodeficient mice and altered
tumor metabolism. Moreover, decreased blood citrate levels have
been associated with some tumors including those in the lung,
bladder, and pancreas (83).
Finally, citrate, upon conversion into isocitrate, can also
fuel itaconate biosynthesis as a TCA cycle by-product from
the decarboxylation of cis-aconitate. Itaconate production
is active in macrophages upon exposure to inflammatory
stimuli, playing a direct antimicrobial effect, markedly
affecting immunomodulation, suppression of inflammation
and tolerance (66). Itaconate acts mainly by inhibiting SDH,
causing accumulation of succinate in LPS activatedmacrophages,
and this was associated to reduced mitochondrial respiration,
ROS production, HIF-1 pseudohypoxic activation, pro-
inflammatory cytokine release, and inflammasome activation
(84). Although itaconate plays clearly a key role within TME by
regulating macrophage activation, its release in TME has not
been yet reported.
Glutamine and Other Aminoacids
Intriguingly, although lactate is the most abundant nutrient
provided in the TME, CAFs are also able to supply amino acids
like glutamine to cancer cells. Epithelial cancer cells incorporate
fibroblasts-derived glutamine replenishing their TCA cycle, as
well as promoting an increase in aspartate-mediated nucleotide
anabolism, the accumulation of oxidized glutathione and the
activation of protein synthesis (85). Glutamine dependency as
it is exploited as a carbon source for the energetic purposes
and as a nitrogen source for nucleotide biosynthesis reflects the
fact such amino acid is the most commonly depleted amino
acid in TME (33). In agreement, glutamine-restricted TME are
truly dependent on tumor-stroma glutamine cross-feeding. In
ovarian carcinoma, CAFs metabolism diverge from classical
glucose exploitation, but activate glutamine synthesis, thereby
serving this amino acid to cancer cells. Hence, due to the
metabolic pressure applied by cancer cells, CAFs increase their
incorporation of glucose-derived carbons into TCA metabolites
and branched-chain amino acids-derived nitrogen to glutamine
synthesis. Cancer cells educate CAFs to enhance their capability
to use different nutrient sources to synthesize glutamine, in
order to support cancer cell mitochondrial activity through
glutaminolysis in stressed TME (86). A similar nutrient cross-
talk mediated by exchanged glutamine has also been reported
in models of astrocytes:glioblastoma and adipocytes:pancreatic
cancer cells, as glutamine fuels the de novo purine biosynthesis
(87, 88). Interestingly, glutamine within TME can also be
active in rescheduling macrophages polarization toward the
malignant M2 phenotype and enhancing cancer aggressiveness.
Indeed, pharmacologic impairment of glutamine synthetase
skewsM2-polarizedmacrophages toward theM1-like phenotype.
As a result of these metabolic changes M2 macrophages
display a decreased ability to recruit immune and endothelial
cells (89).
Beside glutamine, upon stromal autophagy activation,
also alanine is largely secreted by pancreatic stellate cells,
a stromal population very similar to activated CAFs.
Alanine is uploaded by pancreatic cancer cells and fuels
their TCA cycle over the glucose/glutamine-derived
carbons, and this mitochondrial exploitation leads to an
increased biosynthesis of lipids and non-essential amino
acids (90). The metabolic rescheduling of pancreatic
stroma has profound effects on cancer cells, as the
contact with reactive stroma induces widespread histone
acetylation in cancer cells, thereby serving to epigenetic
purposes (91).
Moreover, mechanical signals sent by ECM composition and
stiffness are able to reprogram CAFs and cancer cells toward a
peculiar metabolic cross-talk mediated by exchange of aspartate
and glutamate via the SLC1A3 transporter (92). The cross-talk
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is directional, as CAFs-derived aspartate feeds TCA cycle by
sustaining the pyrimidine biosynthesis in cancer cells exposed
to enhanced ECM stiffness, while glutamate provided by cancer
cells is used by CAFs to maintain redox homeostasis through
glutathione biosynthesis.
Finally, the tumor stroma cross-talk may affect kynurenine
synthesis, a metabolite of tryptophan catabolism, through
activation of the tryptophan 2,3-dioxygenase in CAFs. The
shuttled kynurenine, uploaded by cancer cells, engages the
EMT pathway, enhancing malignancy and immune suppression
through regulation of dendritic and Th1 and Th2 subset of T
cells (93).
Lipids
Lipids are surely key components of TME rescheduling of
cancer cell metabolism. Indeed, lipids can be accumulated in
cells, segregated to lipid droplets (LDs) due to physicochemical
reasons, mainly as triglycerides and cholesterol derivatives.
Their mobilization upon energetic request is under the
control of specific lipases, tightly regulated by TME
stimuli. Catabolism of triglycerides by adipose triglyceride
lipase (ATGL) releases fatty acids (FAs), mainly used
for energetic purposes via TCA cycle fueling, or for
serving acetyl-CoA moieties for acetylation of proteins,
either belonging to nuclear or cytosolic compartments.
Cholesterol can be converted to 22- or 27-hydroxycholesterol,
which activate liver X receptor signaling to up-regulate
cholesterol efflux via regulation of the ATP-binding cassette
transporters (94).
FAs, once released from LDs due to activation of ATGL,
can be delivered to TME for fueling energetic needs of
neighboring cells. To this end lipids can be loaded on secreted
vesicles or translocated across the phospholipid bilayers of the
plasma membrane through either passive diffusion or a protein-
mediated transport system. Several membrane-associated FA
binding proteins and transporters reportedly facilitate the
transport process, including FA translocase (FAT, also named
CD36), Fatty Acid Transport Protein and Plasma Membrane
Fatty Acid Binding Protein. Highly aggressive prostate cancers
show high expression of CD36 which facilitates the intake of
exogenous FAs, and the subsequent LDs mobilization provokes
a significant alteration in intracellular lipid content in terms of
acyl-carnitines, monoacylglycerols and other lysophospholipids
(95). Other findings have found the breast cancer cells resistant
to HER2 therapy upregulate CD36, and thus acquiring an
increased lipid metabolism and metabolic plasticity, both crucial
for promoting resistant cells the adaptation and survival under
nutrient deprivation and drug toxicity (96). Also, hypoxic breast
and glioblastoma cells cancer cells upload FAs from the TME.
The exploitation of triglycerides derived from accumulated
LDs provides them ATP to face conditions of reoxygenation
frequently occurring in a harsh TME (97). To note, stromal
adipocytes are the main lipids donors in TME of several
cancers. During melanoma progression adipocyte-derived lipids
are taken up by FAT proteins, aberrantly expressed in melanoma,
causing lipid upload and enhanced invasion and melanoma cell
growth (98). The translocation of FAs in melanoma cells is
also mediated by vesicles, as indicated by proteomic analysis
of peritumoral adipocyte exosomes, rich in either lipids and
enzymes involved in their catabolism (99). Moreover, in ovarian
cancers, adipocytes promote tumor progression again through
the provision of FAs. Although the exact mechanism through
which adipocyte-derived FAs are transported into ovarian
carcinoma cells remains uncertain, a role has been proposed
for FAT/CD36 carrier (100). Besides adipocyte predominance
in TME lipid supply, interestingly, levels of n-3 and n-6
polyunsaturated fatty acids (PUFA) and glycerophospholipids
(e.g., phosphatidylcholine) have been highly detected in tumor
cells cultured with endothelial cells (101). Collectively, these
findings demonstrate that FATBPs and CD36 play a key role
in tumor microenvironment metabolic cross-talk, driving the
dependency of tumor cells toward exogenous lipid rewiring
cancer cell metabolism and behavior. Furthermore, adipose-
derived lipids have been also shown to mediate ovarian cancer
chemoresistance (102). Indeed, a lipidomic analysis revealed that
arachidonic acid AA is the key chemo-protective lipid mediator,
although it is not known if arachidonate activity is due to its
uploading or if it acts as a signaling molecule, as its sister
companions prostaglandins. Finally, breast cancer cells promote
lipolysis in peritumoral adipocytes leading to the release of FAs
in the TME (103). Particularly, cancer cell-derived inflammatory
signals induce an adipose triglyceride lipase-dependent catabolic
pathway. The mobilized FAs, upon secretion, are transferred to
cancer cells where they are stored in LDs or used through the
carnitine palmitoyltransferase I-dependent fatty acid β-oxidation
pathway, fueling a high mitochondrial activity.
Mitochondria
Nutrients are not only the unique metabolic molecules to
be exchanges. Strikingly, horizontal transfer of intact and
functional organelles (e.g., mitochondria) from stromal to
cancer cells has been observed in TME. Cancer cells may
exploit traveled mitochondria either to start or boost OXPHOS
metabolism. Indeed, mitochondria-defective cancer cells de
novo acquire mitochondria from TME to rescue a respiration
they cannot carry out (104, 105). Oxidative stress is the
driver for this mitochondrial transfer via cytoplasmic bridges
(tunneling nanotubes) formed between bone marrow-derived
MSCs and recipient leukemic blasts. The final outcome
is an increase in mitochondrial mass, OXPHOS and ATP
production as well as the drug resistance of cancer cells
(106–108). Remarkably, CAFs channel their own mitochondria
through intercellular interactions to further boost metabolism of
OXPHOS-addicted prostate cancer cells. The molecular driver
of such behavior seems to be again the lactate as its presence
putatively enhances the formation of such mitochondria roads.
These de novo achieved mitochondria are finely active for
OXPHOS metabolism, ROS production and EMT promotion
in cancer cells (51). Of note, these exchanges of intact
mitochondria in prostate cancer also occur in xenografts of
mice models and are not restricted to mitochondria-defective
cancer cells.
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Microvesicles
Extracellular vesicles (EVs) trafficking has been recently
described as a new form of intercellular communication
(87), with a high impact on the nutritional exchanges
within tumor microenvironment either directly or indirectly
through the cell-cell exchange of metabolic enzymes. EVs
are approximately spherical structures limited by a lipid
bilayer and containing bioactive components, such as proteins,
lipids and nucleic acids. EVs are secreted by many cell
populations, including fibroblasts (88), hematopoietic-derived
cells, epithelial cells, neurons and tumor cells (109–111). EVs
are classified into two main distinct subtypes, depending on
their biogenesis, size, morphology and protein composition:
exosomes and ectosomes/microvesicles (112). Exosomes are
vesicles with a diameter of 50–150 nm, which are formed
via inward budding of late endosomes membrane, the
so called multivesicular bodies, which can fuse with the
plasma membrane, releasing exosomes into the extracellular
environment. On the other hand, microvesicles are directly
produced by plasma membrane blebbing, are larger than
exosomes, ranging from 100 nm to 1µm in diameter (113).
Once released into the extracellular environment they can
interact to recipient cells receptors thereby triggering signal
transduction events or they can fuse with the plasma-
membrane of the acceptor cell releasing their content in
the cytoplasm. EVs trafficking is involved in both physiological
and pathological contexts such as: immunity (114), tissue
regeneration (115), stem cell biology (116), angiogenesis
(117), and tumor progression (118). Here we will focus
our attention on EVs mediated-cross-talk in the context of
tumor microenvironment. Tumor derived EVs are classically
viewed as a way to alter tumor microenvironment to facilitate
cancer progression via the transfer of proteins such as:
(i) epidermal growth factor receptor-vIII, an oncogenic
receptor (119); (ii) multidrug resistance-associated protein
1 a membrane protein mediating export of organic anions
and drugs from the cytoplasm (120); (iii) pro-angiogenic
proteins, i.e., TGF-β and VEGF, etc. (121). In addition, miRNA
transferred by cancer EVs induce, by means of a still unknown
mechanism, the secretion of CAFs chemokines such as CXCL1
and CXCL8 that correlate with poorer survival in gastric
cancer patients (122).
More recently, it has become evident that CAFs are also
able to produce and secrete EVs, thereby underlining the bi-
directional importance of EVs trafficking within TME. Proteins
and miRNA produced by CAFs and conveyed through EVs
to tumor cells influence their behavior, supporting cancer
cells growth rate and survival (123, 124), aggressiveness (125,
126) and favoring chemoresistance (127). In addition, CAF-
derived EVs, uploaded by tumor cells, induce metabolic changes
in acceptor cells such as enhanced glycolysis and glutamine
metabolism rate, decreased oxygen consumption rate and
down-regulation of mitochondrial function (128). The growing
evidences about the involvement of EVs trafficking in regulating
tumor cells metabolism has pushing the focus on the study
of EV-transferred metabolites between different subsets of cells
within tumor microenvironment. EVs-mediated trafficking of
metabolites may be of particular importance for cancer cells
that need a very high rate of metabolites influx to sustain
their rapid cell growth. Currently, metabolomic studies on EVs
has addressed their metabolic content in terms of lipids. It is
reported that EVs transport plasma-membrane derived lipids
i.e., sphingolipids, sterols, glycerophospholipids, fatty acids, and
sphingolipids (129–131), with different relative proportion and
composition reflecting those of their parental cells. Fewer studies
are currently available describing the complete metabolome of
the EVs, but what it is clearly emerging that, besides lipids,
EVs contain many other organic molecules such as vitamins,
amino acids, sugars, nucleotides, carnitines and aromatic
compounds (128, 132, 133).
However, a very efficient way to induce a change in
recipient cells phenotype, with respect to the simple transport
of metabolites, is the transfer of enzymes involved in cellular
metabolism. The analysis of the “vesiclepedia” database using
informatics tools that clusterize the proteins contained into the
EVs using a functional criterion, reveals that over 25% of them
are directly involved in cell metabolism (113). In this view,
EVs trafficking can be seen also as a metabolic coordination
platform between the different cell populations within the solid
tumor. This “metabolic synchronization” allows the optimization
of the overall request for metabolites between the various cellular
components of the tumor in order to support the survival and the
neoplastic expansion of the tissue.
SUMMARY
Tumor-stroma metabolic cross-talk mainly portrays the setting
where tumor confiscates metabolic nutrients, including
lactate, amino acids and fatty acids, from local and/or
stromal sources. This event provokes the catabolic pathways,
such as autophagy, glycolysis and lipolysis in the tumor-
associated cellular compartment. This interplay is absolutely
reciprocal, as the interactions between stromal and tumor cells
mutually reprogram the metabolism of each cell population.
Highly aggressive cancer cells experience specific metabolic
reprogramming, aimed at optimizing and functionally exploiting
stromal cues (i.e., metabolites, vesicles, organelles), likely
representing the critical transducers of the rewiring of the cancer
metabolism within the TME. Stromal-induced mitochondrial
dysregulation, in terms of oncometabolites production, ROS
production and organelle biogenesis or transfer, contributes
to the proliferative and metastatic potential of neoplastic cells.
The flexibility that metabolic deregulation of cancer cells upon
education by TME, often referred as metabolic plasticity,
provides tumor cells the correct tools to face environmental
hostile conditions.
Few therapeutic approaches have been developed to target
tumor:stroma:metabolic interplay, among these we can cite
glycolytic inhibitors to target the stromal component or
pseudohypoxic cancer cells, or mitochondrial inhibitors for
targeting mitochondrial metabolism in OXPHOS-addicted
populations (134). The main obstacle in such targeting
is the metabolic plasticity arising in this stroma-cancer
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communication: any strategy targeting one side of the
tandem rapidly results in rescue of the other part of
the tandem, to shift metabolism toward adaptation to
dynamic environment. Although repurposing efforts to
develop new metabolic inhibitors for cancer therapy to
implement treatments is highly warranted, the preliminary
strongest effort needed right now is the identification
of the molecular player of metabolic plasticity, in order
to efficiently target the adaptive symbiosis of tumor:
stroma tandem.
AUTHOR CONTRIBUTIONS
PCh, PCi, LI, and GC contributed to the writing of this
manuscript. Figure was rendered by LI. Editing was performed
by all authors of this paper.
FUNDING
This work was supported by PRIN 2017 (grant to PCh) and
Fondazione CR Firenze, AIRC (grant 19515 to PCh).
REFERENCES
1. Servais C, Erez N. From sentinel cells to inflammatory culprits: cancer-
associated fibroblasts in tumour-related inflammation. J Pathol. (2013)
229:198–207. doi: 10.1002/path.4103
2. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer.
(2016) 16:582–98. doi: 10.1038/nrc.2016.73
3. Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin.
Am J Cancer Res. (2011) 1:482−97.
4. Comito G, Giannoni E, Segura CP, Barcellos-de-Souza P, Raspollini MR,
Baroni G, et al. Cancer-associated fibroblasts andM2-polarizedmacrophages
synergize during prostate carcinoma progression.Oncogene. (2014) 33:2423–
31. doi: 10.1038/onc.2013.191
5. Comito G, Iscaro A, Bacci M, Morandi A, Ippolito L, Parri M,
et al. Lactate modulates CD4+ T-cell polarization and induces an
immunosuppressive environment, which sustains prostate carcinoma
progression via TLR8/miR21 axis. Oncogene. (2019) 38:3681–95.
doi: 10.1038/s41388-019-0688-7
6. Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, et al.
Reciprocal activation of prostate cancer cells and cancer-associated
fibroblasts stimulates epithelial-mesenchymal transition and cancer
stemness. Cancer Res. (2010) 70:6945–56. doi: 10.1158/0008-5472.
CAN-10-0785
7. Duda DG, Duyverman AMMJ, Kohno M, Snuderl M, Steller EJA, Fukumura
D, et al. Malignant cells facilitate lung metastasis by bringing their own soil.
Proc Natl Acad Sci USA. (2010) 107:21677–82. doi: 10.1073/pnas.1016234107
8. Hill BS, Pelagalli A, Passaro N, Zannetti A. Tumor-educated mesenchymal
stem cells promote pro-metastatic phenotype. Oncotarget. (2017) 8:73296–
311. doi: 10.18632/oncotarget.20265
9. Borriello L, Nakata R, Sheard MA, Fernandez GE, Sposto R, Malvar J,
et al. Cancer-Associated fibroblasts share characteristics and protumorigenic
activity with mesenchymal stromal cells. Cancer Res. (2017) 77:5142–57.
doi: 10.1158/0008-5472.CAN-16-2586
10. Mishra PJ, Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov
JP, et al. Carcinoma-associated fibroblast-like differentiation of
human mesenchymal stem cells. Cancer Res. (2008) 68:4331–9.
doi: 10.1158/0008-5472.CAN-08-0943
11. Han Z, Tian Z, Lv G, Zhang L, Jiang G, Sun K, et al. Immunosuppressive
effect of bone marrow-derived mesenchymal stem cells in inflammatory
microenvironment favours the growth of B16 melanoma cells. J Cell Mol
Med. (2011) 15:2343–52. doi: 10.1111/j.1582-4934.2010.01215.x
12. Cheng J, Li L, Liu Y, Wang Z, Zhu X, Bai X. Interleukin-1α
induces immunosuppression by mesenchymal stem cells promoting
the growth of prostate cancer cells. Mol Med Rep. (2012) 6:955–60.
doi: 10.3892/mmr.2012.1019
13. Butler JM, Kobayashi H, Rafii S. Instructive role of the vascular niche in
promoting tumour growth and tissue repair by angiocrine factors. Nat Rev
Cancer. (2010) 10:138–46. doi: 10.1038/nrc2791
14. Wieland E, Rodriguez-Vita J, Liebler SS, Mogler C, Moll I, Herberich SE,
et al. Endothelial notch1 activity facilitates metastasis. Cancer Cell. (2017)
31:355–67. doi: 10.1016/j.ccell.2017.01.007
15. Qian B-Z, Pollard JW. Macrophage diversity enhances tumor progression
and metastasis. Cell. (2010) 141:39–51. doi: 10.1016/j.cell.2010.03.014
16. Mantovani A, Sica A. Macrophages, innate immunity and cancer:
balance, tolerance, and diversity. Curr Opin Immunol. (2010) 22:231–7.
doi: 10.1016/j.coi.2010.01.009
17. Chaudhary B, Elkord E. Regulatory T cells in the tumor microenvironment
and cancer progression: role and therapeutic targeting. Vaccines. (2016)
4:E28. doi: 10.3390/vaccines4030028
18. Gyamfi J, Lee Y-H, EomM, Choi J. Interleukin-6/STAT3 signalling regulates
adipocyte induced epithelial-mesenchymal transition in breast cancer cells.
Sci Rep. (2018) 8:8859. doi: 10.1038/s41598-018-27184-9
19. Choi J, Cha YJ, Koo JS. Adipocyte biology in breast cancer: from
silent bystander to active facilitator. Prog Lipid Res. (2018) 69:11–20.
doi: 10.1016/j.plipres.2017.11.002
20. Zhou W, Guo S, Gonzalez-Perez RR. Leptin pro-angiogenic signature in
breast cancer is linked to IL-1 signalling. Br J Cancer. (2011) 104:128–37.
doi: 10.1038/sj.bjc.6606013
21. Morandi A, Giannoni E, Chiarugi P. Nutrient exploitation within
the tumor-stroma metabolic crosstalk. Trends Cancer. (2016) 2:736–46.
doi: 10.1016/j.trecan.2016.11.001
22. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism.
Cell Metab. (2016) 23:27–47. doi: 10.1016/j.cmet.2015.12.006
23. Zhang ZZ, Lee EE, Sudderth J, Yue Y, Zia A, Glass D, et al. Glutathione
depletion, pentose phosphate pathway activation, and hemolysis in
erythrocytes protecting cancer cells from vitamin c-induced oxidative stress.
J Biol Chem. (2016) 291:22861–67. doi: 10.1074/jbc.C116.748848
24. Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC,
et al. Glutathione and thioredoxin antioxidant pathways synergize to
drive cancer initiation and progression. Cancer Cell. (2015) 27:211–22.
doi: 10.1016/j.ccell.2014.11.019
25. Sullivan LB, Martinez-Garcia E, Nguyen H, Mullen AR, Dufour E,
Sudarshan S, et al. The proto-oncometabolite fumarate binds glutathione
to amplify ROS-dependent signaling. Mol Cell. (2013) 51:236–48.
doi: 10.1016/j.molcel.2013.05.003
26. Anderton B, Camarda R, Balakrishnan S, Balakrishnan A, Kohnz RA,
Lim L, et al. MYC-driven inhibition of the glutamate-cysteine ligase
promotes glutathione depletion in liver cancer. EMBO Rep. (2017) 18:569–
85. doi: 10.15252/embr.201643068
27. Cheteh EH, Augsten M, Rundqvist H, Bianchi J, Sarne V, Egevad L,
et al. Human cancer-associated fibroblasts enhance glutathione levels and
antagonize drug-induced prostate cancer cell death. Cell Death Dis. (2017)
8:e2848. doi: 10.1038/cddis.2017.225
28. Wang W, Kryczek I, Dostál L, Lin H, Tan L, Zhao L, et al. Effector T cells
abrogate stroma-mediated chemoresistance in ovarian cancer. Cell. (2016)
165:1092–105. doi: 10.1016/j.cell.2016.04.009
29. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass
AJ, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and
contributes to oncogenesis. Nat Genet. (2011) 43:869–74. doi: 10.1038/
ng.890
30. Ippolito L, Morandi A, Giannoni E, Chiarugi P. Lactate: a metabolic
driver in the tumour landscape. Trends Biochem Sci. (2019) 44:153–66.
doi: 10.1016/j.tibs.2018.10.011
31. Grunt TW. Interacting cancer machineries: cell signaling, lipid
metabolism, and epigenetics. Trends Endocrinol Metab. (2018) 29:86–98.
doi: 10.1016/j.tem.2017.11.003
Frontiers in Oncology | www.frontiersin.org 10 March 2020 | Volume 10 | Article 396
Comito et al. Nutritional Exchanges Within Tumor Microenvironment
32. Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi
F, Trentin GA, et al. Dysregulation of the mevalonate pathway
promotes transformation. Proc Natl Acad Sci USA. (2010) 107:15051–6.
doi: 10.1073/pnas.0910258107
33. Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine metabolism
in cancer: understanding the heterogeneity. Trends Cancer. (2017) 3:169–80.
doi: 10.1016/j.trecan.2017.01.005
34. Jiang L, Shestov AA, Swain P, Yang C, Parker SJ, Wang QA, et al. Reductive
carboxylation supports redox homeostasis during anchorage-independent
growth. Nature. (2016) 532:255–8. doi: 10.1038/nature17393
35. Kinnaird A, Zhao S, Wellen KE, Michelakis ED. Metabolic control
of epigenetics in cancer. Nat Rev Cancer. (2016) 16:694–707.
doi: 10.1038/nrc.2016.82
36. Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung Y-L, et al. HIF
overexpression correlates with biallelic loss of fumarate hydratase in renal
cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell.
(2005) 8:143–53. doi: 10.1016/j.ccr.2005.06.017
37. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG,
Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis
by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. (2005) 7:77–85.
doi: 10.1016/j.ccr.2004.11.022
38. Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L, et al.
Haem oxygenase is synthetically lethal with the tumour suppressor fumarate
hydratase. Nature. (2011) 477:225–8. doi: 10.1038/nature10363
39. Faubert B, Li KY, Cai L, Hensley CT, Kim J, Zacharias LG, et al.
Lactate metabolism in human lung tumors. Cell. (2017) 171:358–71.e9.
doi: 10.1016/j.cell.2017.09.019
40. Fiaschi T, Marini A, Giannoni E, Taddei ML, Gandellini P, De Donatis
A, et al. Reciprocal metabolic reprogramming through lactate shuttle
coordinately influences tumor-stroma interplay.Cancer Res. (2012) 72:5130–
40. doi: 10.1158/0008-5472.CAN-12-1949
41. Zhang D,Wang Y, Shi Z, Liu J, Sun P, Hou X, et al. Metabolic reprogramming
of cancer-associated fibroblasts by IDH3α downregulation. Cell Rep. (2015)
10:1335–48. doi: 10.1016/j.celrep.2015.02.006
42. Peppicelli S, Toti A, Giannoni E, Bianchini F, Margheri F, Del Rosso M,
et al. Metformin is also effective on lactic acidosis-exposed melanoma
cells switched to oxidative phosphorylation. Cell Cycle Georget Tex. (2016)
15:1908–18. doi: 10.1080/15384101.2016.1191706
43. LeBleu VS, O’Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K,
Haigis MC, et al. PGC-1α mediates mitochondrial biogenesis and oxidative
phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. (2014)
16:992–1003:1–15. doi: 10.1038/ncb3039
44. Sancho P, Burgos-Ramos E, Tavera A, Bou Kheir T, Jagust P, Schoenhals
M, et al. MYC/PGC-1α balance determines the metabolic phenotype and
plasticity of pancreatic cancer stem cells. Cell Metab. (2015) 22:590–605.
doi: 10.1016/j.cmet.2015.08.015
45. Giannoni E, Taddei ML, Morandi A, Comito G, Calvani M, Bianchini F,
et al. Targeting stromal-induced pyruvate kinase M2 nuclear translocation
impairs oxphos and prostate cancer metastatic spread. Oncotarget. (2015)
6:24061–74. doi: 10.18632/oncotarget.4448
46. Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Sarti M, et al.
Compartmentalized activities of the pyruvate dehydrogenase complex
sustain lipogenesis in prostate cancer. Nat Genet. (2018) 50:219–28.
doi: 10.1038/s41588-017-0026-3
47. Hui S, Ghergurovich JM, Morscher RJ, Jang C, Teng X, Lu W, et al.
Glucose feeds the TCA cycle via circulating lactate.Nature. (2017) 551:115–8.
doi: 10.1038/nature24057
48. Santi A, Caselli A, Paoli P, Corti D, Camici G, Pieraccini G, et al. The effects
of CA IX catalysis products within tumor microenvironment. Cell Commun
Signal. (2013) 11:81. doi: 10.1186/1478-811X-11-81
49. Iessi E, Logozzi M, Mizzoni D, Di Raimo R, Supuran CT, Fais
S. Rethinking the combination of proton exchanger inhibitors in
cancer therapy. Metabolites. (2017) 8:E2. doi: 10.3390/metabo80
10002
50. García-Cañaveras JC, Chen L, Rabinowitz JD. The tumor metabolic
microenvironment: lessons from lactate. Cancer Res. (2019) 79:3155–62.
doi: 10.1158/0008-5472.CAN-18-3726
51. Ippolito L, Morandi A, Taddei ML, Parri M, Comito G, Iscaro A, et al.
Cancer-associated fibroblasts promote prostate cancer malignancy via
metabolic rewiring and mitochondrial transfer. Oncogene. (2019) 38:5339–
55. doi: 10.1038/s41388-019-0805-7
52. Noor SI, Jamali S, Ames S, Langer S, Deitmer JW, Becker HM. A surface
proton antenna in carbonic anhydrase II supports lactate transport in cancer
cells. eLife. (2018) 7:e35176. doi: 10.7554/eLife.35176
53. Corbet C, Draoui N, Polet F, Pinto A, Drozak X, Riant O, et al. The
SIRT1/HIF2α axis drives reductive glutamine metabolism under chronic
acidosis and alters tumor response to therapy. Cancer Res. (2014) 74:5507–
19. doi: 10.1158/0008-5472.CAN-14-0705
54. Lamonte G, Tang X, Chen JL-Y, Wu J, Ding C-KC, Keenan MM,
et al. Acidosis induces reprogramming of cellular metabolism to mitigate
oxidative stress. Cancer Metab. (2013) 1:23. doi: 10.1186/2049-3002-1-23
55. Corbet C, Pinto A, Martherus R, Santiago de Jesus JP, Polet F, Feron
O. Acidosis drives the reprogramming of fatty acid metabolism in cancer
cells through changes in mitochondrial and histone acetylation. Cell Metab.
(2016) 24:311–23. doi: 10.1016/j.cmet.2016.07.003
56. Corbet C, Bastien E, Santiago de Jesus JP, Dierge E, Martherus R, Vander
Linden C, et al. TGFβ2-induced formation of lipid droplets supports
acidosis-driven EMT and the metastatic spreading of cancer cells. Nat
Commun. (2020) 11:454. doi: 10.1038/s41467-019-14262-3
57. Colegio OR, Chu N-Q, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al.
Functional polarization of tumour-associated macrophages by tumour-
derived lactic acid. Nature. (2014) 513:559–63. doi: 10.1038/nature13490
58. Végran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx
through the endothelial cell monocarboxylate transporter MCT1 supports
an NF-κB/IL-8 pathway that drives tumor angiogenesis. Cancer Res. (2011)
71:2550–60. doi: 10.1158/0008-5472.CAN-10-2828
59. Ristic B, Bhutia YD, Ganapathy V. Cell-surface G-protein-coupled receptors
for tumor-associated metabolites: a direct link to mitochondrial dysfunction
in cancer. Biochim Biophys Acta Rev Cancer. (2017) 1868:246–57.
doi: 10.1016/j.bbcan.2017.05.003
60. Cai T-Q, Ren N, Jin L, Cheng K, Kash S, Chen R, et al. Role of GPR81
in lactate-mediated reduction of adipose lipolysis. Biochem Biophys Res
Commun. (2008) 377:987–91. doi: 10.1016/j.bbrc.2008.10.088
61. Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, et al. Metabolic
regulation of gene expression by histone lactylation.Nature. (2019) 574:575–
80. doi: 10.1038/s41586-019-1678-1
62. Yang M, Soga T, Pollard PJ. Oncometabolites: linking altered metabolism
with cancer. J Clin Invest. (2013) 123:3652–8. doi: 10.1172/JCI67228
63. Lefebvre M, Foulkes WD. Pheochromocytoma and paraganglioma
syndromes: genetics and management update. Curr Oncol Tor Ont.
(2014) 21:e8–17. doi: 10.3747/co.21.1579
64. Gill AJ. Succinate dehydrogenase (SDH)-deficient neoplasia.Histopathology.
(2018) 72:106–16. doi: 10.1111/his.13277
65. Mu P, Akashi T, Lu F, Kishida S, Kadomatsu K. A novel nuclear complex
of DRR1, F-actin and COMMD1 involved in NF-κB degradation and
cell growth suppression in neuroblastoma. Oncogene. (2017) 36:5745–56.
doi: 10.1038/onc.2017.181
66. Lampropoulou V, Sergushichev A, Bambouskova M, Nair S, Vincent EE,
Loginicheva E, et al. Itaconate links inhibition of succinate dehydrogenase
with macrophage metabolic remodeling and regulation of inflammation. Cell
Metab. (2016) 24:158–66. doi: 10.1016/j.cmet.2016.06.004
67. Zhao T, Mu X, You Q. Succinate: an initiator in tumorigenesis and
progression. Oncotarget. (2017) 8:53819–28. doi: 10.18632/oncotarget.17734
68. Tretter L, Patocs A, Chinopoulos C. Succinate, an intermediate in
metabolism, signal transduction, ROS, hypoxia, and tumorigenesis.
Biochim Biophys Acta. (2016) 1857:1086–101. doi: 10.1016/j.bbabio.2016.
03.012
69. Wang G, Meyer JG, Cai W, Softic S, Li ME, Verdin E, et al.
Regulation of UCP1 and mitochondrial metabolism in brown adipose
tissue by reversible succinylation. Mol Cell. (2019) 74:844–57.e7.
doi: 10.1016/j.molcel.2019.03.021
70. Gilissen J, Jouret F, Pirotte B, Hanson J. Insight into SUCNR1
(GPR91) structure and function. Pharmacol Ther. (2016) 159:56–65.
doi: 10.1016/j.pharmthera.2016.01.008
Frontiers in Oncology | www.frontiersin.org 11 March 2020 | Volume 10 | Article 396
Comito et al. Nutritional Exchanges Within Tumor Microenvironment
71. Mills E, O’Neill LAJ. Succinate: a metabolic signal in inflammation. Trends
Cell Biol. (2014) 24:313–20. doi: 10.1016/j.tcb.2013.11.008
72. Sapieha P, Sirinyan M, Hamel D, Zaniolo K, Joyal J-S, Cho J-H, et al. The
succinate receptor GPR91 in neurons has amajor role in retinal angiogenesis.
Nat Med. (2008) 14:1067–76. doi: 10.1038/nm.1873
73. Weber A, Klocker H, Oberacher H, Gnaiger E, Neuwirt H, Sampson N,
et al. Succinate accumulation is associated with a shift of mitochondrial
respiratory control and HIF-1α upregulation in PTEN negative prostate
cancer cells. Int J Mol Sci. (2018) 19:E2129. doi: 10.3390/ijms19072129
74. Rubic T, Lametschwandtner G, Jost S, Hinteregger S, Kund J, Carballido-
Perrig N, et al. Triggering the succinate receptor GPR91 on dendritic cells
enhances immunity. Nat Immunol. (2008) 9:1261–9. doi: 10.1038/ni.1657
75. Chouchani ET, Pell VR, Gaude E, Aksentijević D, Sundier SY, Robb EL, et al.
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